Prevalence and Outcome of Secondary Hypogonadism in Male Patients with Cushing's Syndrome and Mild Autonomous Cortisol Secretion.

Cushing’s syndrome cortisol hypogonadism mild autonomous cortisol secretion testosterone

Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
29 Jul 2024
Historique:
received: 29 03 2024
revised: 19 06 2024
accepted: 25 06 2024
medline: 29 7 2024
pubmed: 29 7 2024
entrez: 29 7 2024
Statut: aheadofprint

Résumé

Secondary hypogonadism (SH) is common in men with Cushing's syndrome (CS), but its impact on comorbidities is largely unknown and longitudinal data are scarce. If SH also affects men with mild autonomous cortisol secretion (MACS) is unknown. We included 30 treatment-naïve adult men with CS and 17 men with MACS diagnosed since 2012. Hypogonadism was diagnosed based on total testosterone (TT) concentrations <10.4 nmol/L and age-specific cut-offs. Outcomes were compared to age- and BMI-matched controls. In 20 men in remission of CS, a longitudinal analysis was conducted at 6, 12, and 24 months. Men with CS had significantly lower concentrations of TT, bioavailable T, and free T compared to controls (p<0.0001) with lowest concentrations in ectopic CS. Likewise, TT was lower in men with MACS compared to controls. At baseline, 93% of men with CS and 59% of men with MACS had SH. Testosterone correlated negatively with late night salivary cortisol and serum cortisol pre- and post 1 mg dexamethasone suppression test. Following successful surgery, TT increased significantly (p=0.001), normalising within six months. Despite normalisation, several RBC parameters remained lower in men with CS even two years after successful surgery. SH is common in men with CS and MACS but usually reversible after successful surgery. The persisting changes observed in RBC parameters need to be further investigated in larger cohorts and longer follow-up durations.

Sections du résumé

BACKGROUND BACKGROUND
Secondary hypogonadism (SH) is common in men with Cushing's syndrome (CS), but its impact on comorbidities is largely unknown and longitudinal data are scarce. If SH also affects men with mild autonomous cortisol secretion (MACS) is unknown.
METHODS METHODS
We included 30 treatment-naïve adult men with CS and 17 men with MACS diagnosed since 2012. Hypogonadism was diagnosed based on total testosterone (TT) concentrations <10.4 nmol/L and age-specific cut-offs. Outcomes were compared to age- and BMI-matched controls. In 20 men in remission of CS, a longitudinal analysis was conducted at 6, 12, and 24 months.
RESULTS RESULTS
Men with CS had significantly lower concentrations of TT, bioavailable T, and free T compared to controls (p<0.0001) with lowest concentrations in ectopic CS. Likewise, TT was lower in men with MACS compared to controls. At baseline, 93% of men with CS and 59% of men with MACS had SH. Testosterone correlated negatively with late night salivary cortisol and serum cortisol pre- and post 1 mg dexamethasone suppression test. Following successful surgery, TT increased significantly (p=0.001), normalising within six months. Despite normalisation, several RBC parameters remained lower in men with CS even two years after successful surgery.
CONCLUSION CONCLUSIONS
SH is common in men with CS and MACS but usually reversible after successful surgery. The persisting changes observed in RBC parameters need to be further investigated in larger cohorts and longer follow-up durations.

Identifiants

pubmed: 39074212
pii: 7723629
doi: 10.1093/ejendo/lvae097
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

Elisabeth Nowak (E)

Department of Medicine IV, LMU University Hospital, LMU Munich, Germany.

Frederick Vogel (F)

Department of Medicine IV, LMU University Hospital, LMU Munich, Germany.

Leah Braun (L)

Department of Medicine IV, LMU University Hospital, LMU Munich, Germany.

Stephanie Zopp (S)

Department of Medicine IV, LMU University Hospital, LMU Munich, Germany.

German Rubinstein (G)

Department of Medicine IV, LMU University Hospital, LMU Munich, Germany.

Katharina Schilbach (K)

Department of Medicine IV, LMU University Hospital, LMU Munich, Germany.
Deggendorf Institute of Technology, Deggendorf, Germany.

Martin Bidlingmaier (M)

Department of Medicine IV, LMU University Hospital, LMU Munich, Germany.

Petra Zimmermann (P)

Department of General, Visceral and Transplantation Surgery, LMU University Hospital, LMU Munich, Germany.

Jun Thorsteinsdottir (J)

Department of Neurosurgery, LMU University Hospital, LMU Munich, Germany.

Júnia Schweizer (J)

Department of Medicine IV, LMU University Hospital, LMU Munich, Germany.

Katrin Ritzel (K)

Department of Medicine IV, LMU University Hospital, LMU Munich, Germany.

Felix Beuschlein (F)

Department of Medicine IV, LMU University Hospital, LMU Munich, Germany.
Department of Endocrinology, Diabetology, and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland.
The LOOP Zurich - Medical Research Center, Zurich, Switzerland.

Martin Reincke (M)

Department of Medicine IV, LMU University Hospital, LMU Munich, Germany.

Classifications MeSH